Qprotyn
Qprotyn offers a patented platform technology, HILOPRO®, that reduces the viscosity of monoclonal antibodies (mAbs) to enable subcutaneous (SubQ) delivery. This technology utilizes GRAS excipients to reformulate mAbs from intravenous (IV) to SubQ administration, allowing for higher concentrations and reduced injection frequency. The HILOPRO® system facilitates the development of single-dose subcutaneous injections with up to 450mg in a 1.5mL syringe, improving patient convenience and market acceptance. Qprotyn's approach is a systems approach that combines formulation technology with delivery devices like syringes, wearables, or auto-injectors, providing a cost-effective method for converting IV formulations to SubQ.
Qprotyn
Qprotyn offers a patented platform technology, HILOPRO®, that reduces the viscosity of monoclonal antibodies (mAbs) to enable subcutaneous (SubQ) delivery. This technology utilizes GRAS excipients to reformulate mAbs from intravenous (IV) to SubQ administration, allowing for higher concentrations and reduced injection frequency. The HILOPRO® system facilitates the development of single-dose subcutaneous injections with up to 450mg in a 1.5mL syringe, improving patient convenience and market acceptance. Qprotyn's approach is a systems approach that combines formulation technology with delivery devices like syringes, wearables, or auto-injectors, providing a cost-effective method for converting IV formulations to SubQ.